Kaposi sarcoma-associated herpesvirus-associated malignancies: Epidemiology, pathogenesis, and advances in treatment

Seminars in Oncology

Volumn 42, Issue 2, 2015, Pages 223-246

  Bhutani, Manisha ^a   Polizzotto, Mark N ^a   Uldrick, Thomas S ^a   Yarchoan, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 6; LATENCY ASSOCIATED NUCLEAR ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA SOUTH OF THE SAHARA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIVIRAL THERAPY; DISEASE COURSE; DNA SEQUENCE; EFFUSION; HOST CELL; HUMAN; HUMAN HERPESVIRUS 8; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; MACROPHAGE; MIXED INFECTION; MOLECULAR DIAGNOSTICS; NONHUMAN; ORGAN TRANSPLANTATION; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROPREVALENCE; SEXUAL TRANSMISSION; SIGNAL TRANSDUCTION; SOUTHERN EUROPE; SPINDLE CELL; TUMOR MICROENVIRONMENT; COMPLICATION; HERPESVIRIDAE INFECTIONS; NEOPLASMS; VIROLOGY;

HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; NEOPLASMS; SEROEPIDEMIOLOGIC STUDIES;

EID: 84926309600     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.12.027     Document Type: Review

References (202)

1. Y. Chang, E. Cesarman, and M.S. Pessin Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma Science 266 1994 1865 1869
2. P.S. Moore, and Y. Chang Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection N Engl J Med 332 1995 1181 1185
3. Y. Chang, J. Ziegler, and H. Wabinga Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group Arch Intern Med 156 1996 202 204
4. N. Dupin, M. Grandadam, and V. Calvez Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma Lancet 345 1995 761 762
5. E. Cesarman, Y. Chang, P.S. Moore, J.W. Said, and D.M. Knowles Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas N Engl J Med 332 1995 1186 1191
6. J. Soulier, L. Grollet, and E. Oksenhendler Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease Blood 86 1995 1276 1280
7. P. Cook-Mozaffari, R. Newton, V. Beral, and D.P. Burkitt The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic Br J Cancer 78 1998 1521 1528
8. O. Klepp, O. Dahl, and J.T. Stenwig Association of Kaposi's sarcoma and prior immunosuppressive therapy: a 5-year material of Kaposi's sarcoma in Norway Cancer 42 1978 2626 2630
9. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California MMWR Morb Mortal Wkly Rep 30 1981 305 308
10. R.M. Selik, H.W. Haverkos, and J.W. Curran Acquired immune deficiency syndrome (AIDS) trends in the United States, 1978-1982 Am J Med 76 1984 493 500
11. V. Beral, T.A. Peterman, R.L. Berkelman, and H.W. Jaffe Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 335 1990 123 128
12. D. Whitby, M.R. Howard, and M. Tenant-Flowers Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma Lancet 346 1995 799 802
13. S.J. Gao, L. Kingsley, and D.R. Hoover Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma N Engl J Med 335 1996 233 241
14. V. Bouvard, R. Baan, and K. Straif A review of human carcinogens - Part B: biological agents Lancet Oncol 10 2009 321 322
15. M.S. Shiels, R.M. Pfeiffer, and M.H. Gail Cancer burden in the HIV-infected population in the United States J Natl Cancer Inst 103 2011 753 762
16. Center for Disease Control and Prevention Estimated HIV incidence in the United States, 2007-2010 HIV Surveillance Supplemental Report 2012
17. H.R. Wabinga, S. Nambooze, P.M. Amulen, C. Okello, L. Mbus, and D.M. Parkin Trends in the incidence of cancer in Kampala, Uganda 1991-2010 Int J Cancer 135 2014 432 439
18. N. Labo, W. Miley, and V. Marshall Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome PLoS Pathog 10 2014 e1004046
19. S.J. Gao, L. Kingsley, and M. Li KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma Nat Med 2 1996 925 928
20. G.R. Simpson, T.F. Schulz, and D. Whitby Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen Lancet 348 1996 1133 1138
21. G.L. Mbisa, W. Miley, and C.J. Gamache Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: A new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA J Immunol Methods 2010
22. E.A. Engels, D. Whitby, and P.B. Goebel Identifying human herpesvirus 8 infection: performance characteristics of serologic assays J Acquir Immune Defic Syndr 23 2000 346 354
23. P.D. Burbelo, H.P. Leahy, and S. Groot Four-antigen mixture containing v-cyclin for serological screening of human herpesvirus 8 infection Clin Vaccine Immunol 16 2009 621 627
24. J. Zong, D.M. Ciufo, and R. Viscidi Genotypic analysis at multiple loci across Kaposi's sarcoma herpesvirus (KSHV) DNA molecules: clustering patterns, novel variants and chimerism J Clin Virol 23 2002 119 148
25. D.H. Osmond, S. Buchbinder, and A. Cheng Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic JAMA 287 2002 221 225
26. D. Whitby, M. Luppi, P. Barozzi, C. Boshoff, R.A. Weiss, and G. Torelli Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy J Natl Cancer Inst 90 1998 395 397
27. R.J. Biggar, D. Whitby, V. Marshall, A.C. Linhares, and F. Black Human herpesvirus 8 in Brazilian Amerindians: a hyperendemic population with a new subtype J Infect Dis 181 2000 1562 1568
28. G. Rezza, R.T. Danaya, and T.M. Wagner Human herpesvirus-8 and other viral infections, Papua New Guinea Emerg Infect Dis 7 2001 893 895
29. X. Wang, B. He, and Z. Zhang Human herpesvirus-8 in northwestern China: epidemiology and characterization among blood donors Virol J 7 2010 62
30. J. Baillargeon, C.T. Leach, J.H. Deng, S.J. Gao, and H.B. Jenson High prevalence of human herpesvirus 8 (HHV-8) infection in south Texas children J Med Virol 67 2002 542 548
31. J.N. Martin, D.E. Ganem, D.H. Osmond, K.A. Page-Shafer, D. Macrae, and D.H. Kedes Sexual transmission and the natural history of human herpesvirus 8 infection N Engl J Med 338 1998 948 954
32. C. Casper, A. Wald, J. Pauk, S.R. Tabet, L. Corey, and C.L. Celum Correlates of prevalent and incident Kaposi's sarcoma-associated herpesvirus infection in men who have sex with men J Infect Dis 185 2002 990 993
33. M. Giuliani, P. Cordiali-Fei, and C. Castilletti Incidence of human herpesvirus 8 (HHV-8) infection among HIV-uninfected individuals at high risk for sexually transmitted infections BMC Infect Dis 7 2007 143
34. F. Sitas, H. Carrara, and V. Beral Antibodies against human herpesvirus 8 in black South African patients with cancer N Engl J Med 340 1999 1863 1871
35. L.M. Butler, G. Dorsey, and W. Hladik Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission J Infect Dis 200 2009 430 438
36. K. Wakeham, E.L. Webb, and I. Sebina Risk factors for seropositivity to Kaposi sarcoma-associated herpesvirus among children in Uganda J Acquir Immune Defic Syndr 63 2013 228 233
37. S.M. Mbulaiteye, R.J. Biggar, and R.M. Pfeiffer Water, socioeconomic factors, and human herpesvirus 8 infection in Ugandan children and their mothers J Acquir Immune Defic Syndr 38 2005 474 479
38. J. Pauk, M.L. Huang, and S.J. Brodie Mucosal shedding of human herpesvirus 8 in men N Engl J Med 343 2000 1369 1377
39. C. Casper, E. Krantz, and S. Selke Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men J Infect Dis 195 2007 30 36
40. M.M. Taylor, B. Chohan, and L. Lavreys Shedding of human herpesvirus 8 in oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan women J Infect Dis 190 2004 484 488
41. S.M. Mbulaiteye, R.J. Biggar, and P.M. Bakaki Human herpesvirus 8 infection and transfusion history in children with sickle-cell disease in Uganda J Natl Cancer Inst 95 2003 1330 1335
42. N.H. Dukers, N. Renwick, and M. Prins Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men Am J Epidemiol 151 2000 213 224
43. D.H. Kedes, E. Operskalski, M. Busch, R. Kohn, J. Flood, and D. Ganem The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission Nat Med 2 1996 918 924
44. E.A. Engels, J.O. Atkinson, and B.I. Graubard Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission J Infect Dis 196 2007 199 207
45. V. Beral, D. Bull, and S. Darby Risk of Kaposi's sarcoma and sexual practices associated with faecal contact in homosexual or bisexual men with AIDS Lancet 339 1992 632 635
46. A.E. Grulich, J.M. Kaldor, O. Hendry, K. Luo, N.J. Bodsworth, and D.A. Cooper Risk of Kaposi's sarcoma and oroanal sexual contact Am J Epidemiol 145 1997 673 679
47. J.A. Ambroziak, D.J. Blackbourn, and B.G. Herndier Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients Science 268 1995 582 583
48. P. Monini, L. de Lellis, M. Fabris, F. Rigolin, and E. Cassai Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen N Engl J Med 334 1996 1168 1172
49. J.M. Baeten, B.H. Chohan, and L. Lavreys Correlates of human herpesvirus 8 seropositivity among heterosexual men in Kenya AIDS 16 2002 2073 2078
50. B.I. Malope, P. MacPhail, and G. Mbisa No evidence of sexual transmission of Kaposi's sarcoma herpes virus in a heterosexual South African population AIDS 22 2008 519 526
51. T.B. Campbell, M. Borok, and B. Ndemera Lack of evidence for frequent heterosexual transmission of human herpesvirus 8 in Zimbabwe Clin Infect Dis 48 2009 1601 1608
52. N. Renwick, T. Halaby, and G.J. Weverling Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma AIDS 12 1998 2481 2488
53. M.J. Cannon, S.C. Dollard, and D.K. Smith Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection N Engl J Med 344 2001 637 643
54. S. Kleinman, M.R. King, M.P. Busch, E.L. Murphy, and S.A. Glynn The National Heart, Lung, and Blood Institute retrovirus epidemiology donor studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): twenty years of research to advance blood product safety and availability Transfus Med Rev 26 2012 281 304
55. W. Hladik, S.C. Dollard, and J. Mermin Transmission of human herpesvirus 8 by blood transfusion N Engl J Med 355 2006 1331 1338
56. N. Regamey, M. Tamm, and M. Wernli Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients N Engl J Med 339 1998 1358 1363
57. P. Barozzi, M. Luppi, and F. Facchetti Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors Nat Med 9 2003 554 561
58. T.J. Dudderidge, M. Khalifa, R. Jeffery, P. Amlot, M. Al-Akraa, and P. Sweny Donor-derived human herpes virus 8-related Kaposi's sarcoma in renal allograft ureter Transpl Infect Dis 10 2008 221 226
59. C. Frances, A.G. Marcelin, and C. Legendre The impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survival Am J Transplant 9 2009 2580 2586
60. G. Pietrosi, G. Vizzini, and L. Pipitone Primary and reactivated HHV8 infection and disease after liver transplantation: a prospective study Am J Transplant 11 2011 2715 2723
61. C. Lebbe, R. Porcher, and A.G. Marcelin Human herpesvirus 8 (HHV8) transmission and related morbidity in organ recipients Am J Transplant 13 2013 207 213
62. R.J. Biggar, A.K. Chaturvedi, J.J. Goedert, and E.A. Engels AIDS-related cancer and severity of immunosuppression in persons with AIDS J Natl Cancer Inst 99 2007 962 972
63. A. Guihot, N. Dupin, and A.G. Marcelin Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma J Infect Dis 194 2006 1078 1088
64. M.J. Silverberg, C. Chao, and W.A. Leyden HIV infection, immunodeficiency, viral replication, and the risk of cancer Cancer Epidemiol Biomarkers Prev 20 2011 2551 2559
65. E.A. Engels, R.M. Pfeiffer, and J.J. Goedert Trends in cancer risk among people with AIDS in the United States 1980-2002 AIDS 20 2006 1645 1654
66. E.P. Simard, R.M. Pfeiffer, and E.A. Engels Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States Cancer 117 2011 1089 1096
67. M. Bower, T. Powles, and S. Williams Brief communication: rituximab in HIV-associated multicentric Castleman disease Ann Intern Med 147 2007 836 839
68. L. Gerard, A. Berezne, and L. Galicier Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial J Clin Oncol 25 2007 3350 3356
69. E.A. Engels, R.M. Pfeiffer, and J.F. Fraumeni Jr Spectrum of cancer risk among US solid organ transplant recipients JAMA 306 2011 1891 1901
70. G. Tessari, L. Naldi, and L. Boschiero Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study Am J Transplant 13 2013 214 221
71. M. Byun, C.S. Ma, and A. Akcay Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood J Exp Med 210 2013 1743 1759
72. M. Byun, A. Abhyankar, and V. Lelarge Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma J Exp Med 207 2010 2307 2312
73. Y. Camcioglu, C. Picard, and V. Lacoste HHV-8-associated Kaposi sarcoma in a child with IFNgammaR1 deficiency J Pediatr 144 2004 519 523
74. C. Picard, F. Mellouli, and R. Duprez Kaposi's sarcoma in a child with Wiskott-Aldrich syndrome Eur J Pediatr 165 2006 453 457
75. W.J. Grossman, M. Radhi, D. Schauer, E. Gerday, C. Grose, and F.D. Goldman Development of hemophagocytic lymphohistiocytosis in triplets infected with HHV-8 Blood 106 2005 1203 1206
76. E.E. Brown, D. Fallin, and I. Ruczinski Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity Cancer Epidemiol Biomarkers Prev 15 2006 926 934
77. C.B. Foster, T. Lehrnbecher, and S. Samuels An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus Blood 96 2000 2562 2567
78. E.E. Brown, D. Whitby, and F. Vitale Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma Cancer 107 2006 2282 2290
79. P. Unemori, K.S. Leslie, and P.W. Hunt Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection AIDS 27 2013 1735 1742
80. T. Powles, J. Stebbing, and A. Bazeos The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease Ann Oncol 20 2009 775 779
81. A. Ray, V. Marshall, and T. Uldrick Sequence analysis of Kaposi sarcoma-associated herpesvirus (KSHV) microRNAs in patients with multicentric Castleman disease and KSHV-associated inflammatory cytokine syndrome J Infect Dis 205 2012 1665 1676
82. O. Flore, S. Rafii, S. Ely, J.J. O'Leary, E.M. Hyjek, and E. Cesarman Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus Nature 394 1998 588 592
83. P.S. Moore, C. Boshoff, R.A. Weiss, and Y. Chang Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV Science 274 1996 1739 1744
84. C. Boshoff, Y. Endo, and P.D. Collins Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines Science 278 1997 290 294
85. D.A. Davis, A.S. Rinderknecht, and J.P. Zoeteweij Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus Blood 97 2001 3244 3250
86. X. Li, J. Feng, and R. Sun Oxidative stress induces reactivation of Kaposi's sarcoma-associated herpesvirus and death of primary effusion lymphoma cells J Virol 85 2011 715 724
87. Y. Zeng, X. Zhang, and Z. Huang Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus: role of JAK/STAT signaling J Virol 81 2007 2401 2417
88. H.J. Shin, J. DeCotiis, M. Giron, D. Palmeri, and D.M. Lukac Histone deacetylase classes I and II regulate Kaposi's sarcoma-associated herpesvirus reactivation J Virol 88 2014 1281 1292
89. H.J. Brown, W.H. McBride, J.A. Zack, and R. Sun Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus Antivir Ther 10 2005 745 751
90. R. Sun, S.F. Lin, L. Gradoville, Y. Yuan, F. Zhu, and G. Miller A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus Proc Natl Acad Sci U S A 95 1998 10866 10871
91. R. Sarid, O. Flore, R.A. Bohenzky, Y. Chang, and P.S. Moore Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1) J Virol 72 1998 1005 1012
92. K.A. Staskus, W. Zhong, and K. Gebhard Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells J Virol 71 1997 715 719
93. M.E. Ballestas, P.A. Chatis, and K.M. Kaye Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen Science 284 1999 641 644
94. R. Renne, C. Barry, D. Dittmer, N. Compitello, P.O. Brown, and D. Ganem Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus J Virol 75 2001 458 468
95. K. Lan, D.A. Kuppers, S.C. Verma, and E.S. Robertson Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virus-mediated control of latency J Virol 78 2004 6585 6594
96. J. Friborg, W. Kong, M.O. Hottiger, and G.J. Nabel p53 inhibition by the LANA protein of KSHV protects against cell death Nature 402 1999 889 894
97. S.A. Radkov, P. Kellam, and C. Boshoff The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells Nat Med 6 2000 1121 1127
98. M. Fujimuro, F.Y. Wu, and C. ApRhys A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency Nat Med 9 2003 300 306
99. K. Lan, S.C. Verma, M. Murakami, B. Bajaj, R. Kaul, and E.S. Robertson Kaposi's sarcoma herpesvirus-encoded latency-associated nuclear antigen stabilizes intracellular activated Notch by targeting the Sel10 protein Proc Natl Acad Sci U S A 104 2007 16287 16292
100. G. Sarek, A. Jarviluoma, and H.M. Moore Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency PLoS Pathog 6 2010 e1000818
101. D. Godden-Kent, S.J. Talbot, and C. Boshoff The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1 J Virol 71 1997 4193 4198
102. D.J. Mann, E.S. Child, C. Swanton, H. Laman, and N. Jones Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus EMBO J 18 1999 654 663
103. M. Thome, P. Schneider, and K. Hofmann Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors Nature 386 1997 517 521
104. P.M. Chaudhary, A. Jasmin, M.T. Eby, and L. Hood Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins Oncogene 18 1999 5738 5746
105. S. Sakakibara, C.A. Pise-Masison, J.N. Brady, and G. Tosato Gene regulation and functional alterations induced by Kaposi's sarcoma-associated herpesvirus-encoded ORFK13/vFLIP in endothelial cells J Virol 83 2009 2140 2153
106. I. Guasparri, S.A. Keller, and E. Cesarman KSHV vFLIP is essential for the survival of infected lymphoma cells J Exp Med 199 2004 993 1003
107. A. Forero, P.S. Moore, and S.N. Sarkar Role of IRF4 in IFN-stimulated gene induction and maintenance of Kaposi sarcoma-associated herpesvirus latency in primary effusion lymphoma cells J Immunol 191 2013 1476 1485
108. J.-S. Lee, Q. Li, and J.-Y. Lee FLIP-mediated autophagy regulation in cell death control Nat Cell Biol 11 2009 1355 1362
109. S. Muralidhar, A.M. Pumfery, and M. Hassani Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene J Virol 72 1998 4980 4988
110. J. Yoo, J. Kang, and H.N. Lee Kaposin-B enhances the PROX1 mRNA stability during lymphatic reprogramming of vascular endothelial cells by Kaposi's sarcoma herpes virus PLoS Pathog 6 2010 e1001046
111. C. McCormick, and D. Ganem The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs Science 307 2005 739 741
112. P. Baresova, P.M. Pitha, and B. Lubyova Distinct roles of Kaposi's sarcoma-associated herpesvirus-encoded viral interferon regulatory factors in inflammatory response and cancer J Virol 87 2013 9398 9410
113. C. Rivas, A.E. Thlick, C. Parravicini, P.S. Moore, and Y. Chang Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53 J Virol 75 2001 429 438
114. E. Wies, Y. Mori, and A. Hahn The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells Blood 111 2008 320 327
115. Y.C. Shin, C.H. Joo, M.U. Gack, H.R. Lee, and J.U. Jung Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 alpha to induce vascular endothelial growth factor expression Cancer Res 68 2008 1751 1759
116. M.A. Samols, J. Hu, R.L. Skalsky, and R. Renne Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus J Virol 79 2005 9301 9305
117. Y. Zhu, I. Haecker, Y. Yang, S.J. Gao, and R. Renne gamma-Herpesvirus-encoded miRNAs and their roles in viral biology and pathogenesis Curr Opin Virol 3 2013 266 275
118. A.M. Gallaher, S. Das, and Z. Xiao Proteomic screening of human targets of viral microRNAs reveals functions associated with immune evasion and angiogenesis PLoS Pathog 9 2013 e1003584
119. J.R. Abend, D. Ramalingam, P. Kieffer-Kwon, T.S. Uldrick, R. Yarchoan, and J.M. Ziegelbauer Kaposi's sarcoma-associated herpesvirus microRNAs target IRAK1 and MYD88, two components of the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression J Virol 86 2012 11663 11674
120. Z. Qin, P. Kearney, K. Plaisance, and C.H. Parsons Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes J Leukoc Biol 87 2010 25 34
121. S.J. Gao, C. Boshoff, S. Jayachandra, R.A. Weiss, Y. Chang, P.S. Moore, and O.R.F. KSHV K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway Oncogene 15 1997 1979 1985
122. D. Lagos, M.W. Trotter, and R.J. Vart Kaposi sarcoma herpesvirus-encoded vFLIP and vIRF1 regulate antigen presentation in lymphatic endothelial cells Blood 109 2007 1550 1558
123. K. Schmidt, E. Wies, and F. Neipel Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression J Virol 85 2011 4530 4537
124. S. Kirchhoff, T. Sebens, and S. Baumann Viral IFN-regulatory factors inhibit activation-induced cell death via two positive regulatory IFN-regulatory factor 1-dependent domains in the CD95 ligand promoter J Immunol 168 2002 1226 1234
125. E. Cesarman, R.G. Nador, and F. Bai Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma J Virol 70 1996 8218 8223
126. T.Y. Yang, S.C. Chen, and M.W. Leach Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma J Exp Med 191 2000 445 454
127. L. Arvanitakis, E. Geras-Raaka, A. Varma, M.C. Gershengorn, and E. Cesarman Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation Nature 385 1997 347 350
128. C. Bais, B. Santomasso, and O. Coso G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator Nature 391 1998 86 89
129. A. Sodhi, S. Montaner, and V. Patel The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha Cancer Res 60 2000 4873 4880
130. A. Sodhi, R. Chaisuparat, and J. Hu The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor Cancer Cell 10 2006 133 143
131. M. Schwarz, and P.M. Murphy Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-kappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant J Immunol 167 2001 505 513
132. M. Chatterjee, J. Osborne, G. Bestetti, Y. Chang, and P.S. Moore Viral IL-6-induced cell proliferation and immune evasion of interferon activity Science 298 2002 1432 1435
133. J. Molden, Y. Chang, Y. You, P.S. Moore, and M.A. Goldsmith A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit J Biol Chem 272 1997 19625 19631
134. Y. Aoki, E.S. Jaffe, and Y. Chang Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 Blood 93 1999 4034 4043
135. T.S. Uldrick, V. Wang, and D. O'Mahony An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without multicentric Castleman disease Clin Infect Dis 51 2010 350 358
136. M.N. Polizzotto, T.S. Uldrick, and V. Wang Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease Blood 122 2013 4189 4198
137. Y. Aoki, R. Yarchoan, J. Braun, A. Iwamoto, and G. Tosato Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions Blood 96 2000 1599 1601
138. D. Chen, G. Sandford, and J. Nicholas Intracellular signaling mechanisms and activities of human herpesvirus 8 interleukin-6 J Virol 83 2009 722 733
139. E. Cousins, and J. Nicholas Role of human herpesvirus 8 interleukin-6-activated gp130 signal transducer in primary effusion lymphoma cell growth and viability J Virol 87 2013 10816 10827
140. J. Suthaus, C. Stuhlmann-Laeisz, and V.S. Tompkins HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice Blood 119 2012 5173 5181
141. B.R. Herts, A.J. Megibow, B.A. Birnbaum, G.K. Kanzer, and M.E. Noz High-attenuation lymphadenopathy in AIDS patients: significance of findings at CT Radiology 185 1992 777 781
142. A. Davidson, R.D. Wainwright, and D.K. Stones Malignancies in South African children with HIV J Pediatr Hematol Oncol 36 2014 111 117
143. Y.K. Hong, K. Foreman, and J.W. Shin Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus Nat Genet 36 2004 683 685
144. L. Pantanowitz, C.N. Otis, and B.J. Dezube Immunohistochemistry in Kaposi's sarcoma Clin Exp Dermatol 35 2010 68 72
145. M.R. Hussein Immunohistological evaluation of immune cell infiltrate in cutaneous Kaposi's sarcoma Cell Biol Int 32 2008 157 162
146. L. Pantanowitz, B.J. Dezube, G.S. Pinkus, and S.R. Tahan Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi's sarcoma J Cutan Pathol 31 2004 26 34
147. S.E. Krown, C. Metroka, and J.C. Wernz Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee J Clin Oncol 7 1989 1201 1207
148. S.E. Krown, M.A. Testa, and J. Huang AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee J Clin Oncol 15 1997 3085 3092
149. A. Mosam, F. Shaik, and T.S. Uldrick A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa J Acquir Immune Defic Syndr 60 2012 150 157
150. G. Nasti, R. Talamini, and A. Antinori AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era - the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals J Clin Oncol 21 2003 2876 2882
151. M. Maskew, M.P. Fox, and G. van Cutsem Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study PLoS One 8 2013 e64392
152. M. Bower, P. Fox, K. Fife, J. Gill, M. Nelson, and B. Gazzard Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma AIDS 13 1999 2105 2111
153. V. Martinez, E. Caumes, and L. Gambotti Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy Br J Cancer 94 2006 1000 1006
154. G. Stallone, A. Schena, and B. Infante Sirolimus for Kaposi's sarcoma in renal-transplant recipients N Engl J Med 352 2005 1317 1323
155. P.S. Gill, J. Wernz, and D.T. Scadden Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma J Clin Oncol 14 1996 2353 2364
156. D.W. Northfelt, B.J. Dezube, and J.A. Thommes Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial J Clin Oncol 16 1998 2445 2451
157. S. Stewart, H. Jablonowski, and F.D. Goebel Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group J Clin Oncol 16 1998 683 691
158. T. Cooley, D. Henry, M. Tonda, S. Sun, M. O'Connell, and W. Rackoff A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma Oncologist 12 2007 114 123
159. L. Welles, M.W. Saville, and J. Lietzau Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma J Clin Oncol 16 1998 1112 1121
160. A. Tulpule, J. Groopman, and M.W. Saville Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma Cancer 95 2002 147 154
161. M. Cianfrocca, S. Lee, and J. Von Roenn Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy Cancer 116 2010 3969 3977
162. S.E. Krown, P. Li, J.H. Von Roenn, J. Paredes, J. Huang, and M.A. Testa Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study J Interferon Cytokine Res 22 2002 295 303
163. F.A. Shepherd, R. Beaulieu, and K. Gelmon Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study J Clin Oncol 16 1998 1736 1742
164. S.R. Evans, S.E. Krown, M.A. Testa, T.P. Cooley, and J.H. Von Roenn Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study J Clin Oncol 20 2002 3236 3241
165. G. Schwartsmann, E. Sprinz, and M. Kromfield Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy J Clin Oncol 15 1997 2118 2124
166. G. Nasti, D. Errante, and R. Talamini Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study J Clin Oncol 18 2000 1550 1557
167. M.W. Saville, J. Lietzau, J.M. Pluda, I. Feuerstein, J. Odom, W.H. Wilson, R.W. Humphrey, E. Feigal, S.M. Steinberg, and S. Broder Treatment of HIV-associated Kaposi's sarcoma with paclitaxel Lancet 346 8966 1995 26 28
168. P.S. Gill, A. Tulpule, and B.M. Espina Paclitaxel is safe and effective in the treatment of advanced AIDS- related Kaposi's sarcoma J Clin Oncol 17 1999 1876 1883
169. S.E. Krown, J.Y. Lee, L. Lin, M.A. Fischl, R. Ambinder, and J.H. Von Roenn Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial J Acquir Immune Defic Syndr 41 2006 149 153
170. K. Fife, M.R. Howard, F. Gracie, R.H. Phillips, and M. Bower Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre Int J STD AIDS 9 1998 751 755
171. R.F. Little, K.M. Wyvill, and J.M. Pluda Activity of thalidomide in AIDS-related Kaposi's sarcoma J Clin Oncol 18 2000 2593 2602
172. S.E. Krown, D. Roy, and J.Y. Lee Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study J Acquir Immune Defic Syndr 59 2012 447 454
173. B.J. Dezube, S.E. Krown, J.Y. Lee, K.S. Bauer, and D.M. Aboulafia Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study J Clin Oncol 24 2006 1389 1394
174. H.B. Koon, S.E. Krown, and J.Y. Lee Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042 J Clin Oncol 32 2014 402 408
175. T.S. Uldrick, K.M. Wyvill, and P. Kumar Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy J Clin Oncol 30 2012 1476 1483
176. D.H. Kedes, and D. Ganem Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy J Clin Invest 99 1997 2082 2086
177. D.F. Martin, B.D. Kuppermann, R.A. Wolitz, A.G. Palestine, H. Li, and C.A. Robinson Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group N Engl J Med 340 1999 1063 1070
178. E. Oksenhendler, M. Duarte, and J. Soulier Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients AIDS 10 1996 61 67
179. E. Oksenhendler, G. Carcelain, and Y. Aoki High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients Blood 96 2000 2069 2073
180. J. An, Y. Sun, R. Sun, and M.B. Rettig Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways Oncogene 22 2003 3371 3385
181. S.A. Keller, D. Hernandez-Hopkins, and J. Vider NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo Blood 107 2006 3295 3302
182. Y. Aoki, G. Tosato, T.W. Fonville, and S. Pittaluga Serum viral interleukin-6 in AIDS-related multicentric Castleman disease Blood 97 2001 2526 2527
183. M.N. Polizzotto, T.S. Uldrick, D. Hu, and R. Yarchoan Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome Front Microbiol 3 2012 73
184. M.Q. Du, H. Liu, and T.C. Diss Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders Blood 97 2001 2130 2136
185. K.N. Naresh, A.J. Rice, and M. Bower Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma Am J Surg Pathol 32 2008 1006 1012
186. T.S. Uldrick, M.N. Polizzotto, and R. Yarchoan Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease Curr Opin Oncol 24 2012 495 505
187. M. Bower, A.D. Pria, C. Coyle, M. Nelson, and K. Naresh Diagnostic criteria schemes for multicentric Castleman disease in 75 cases J Acquir Immune Defic Syndr 65 2014 e80 e82
188. E.E. Mylona, I.G. Baraboutis, L.J. Lekakis, O. Georgiou, V. Papastamopoulos, and A. Skoutelis Multicentric Castleman's disease in HIV infection: a systematic review of the literature AIDS Rev 10 2008 25 35
189. G. Rappocciolo, H.R. Hensler, and M. Jais Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN J Virol 82 2008 4793 4806
190. L. Gerard, J.M. Michot, and S. Burcheri Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease Blood 119 2012 2228 2233
191. T.S. Uldrick, M.N. Polizzotto, K. Aleman, K.M. Wyvill, V. Marshall, D. Whitby, V. Wang, S. Pittaluga, D. O'Mahony, S.M. Steinberg, R.F. Little, and R. Yarchoan Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease Blood 124 24 2014 3522 3552
192. D.A. Davis, K.E. Singer, I.P. Reynolds, M. Haque, and R. Yarchoan Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi's sarcoma-associated herpesvirus infected cells Cancer Res 67 2007 7003 7010
193. T.S. Uldrick, M.N. Polizzotto, and K. Aleman High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy Blood 117 2011 6977 6986
194. R.G. Jenner, K. Maillard, and N. Cattini Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile Proc Natl Acad Sci USA 100 2003 10399 10404
195. U. Klein, A. Gloghini, and G. Gaidano Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts Blood 101 2003 4115 4121
196. S.L. Luan, E. Boulanger, and H. Ye Primary effusion lymphoma: genomic profiling revealed amplification of SELPLG and CORO1C encoding for proteins important for cell migration J Pathol 222 2010 166 179
197. R.G. Nador, E. Cesarman, and A. Chadburn Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus Blood 88 1996 645 656
198. E. Boulanger, L. Gérard, and J. Gabarre Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS J Clin Oncol 23 2005 4372 4380
199. A. Chadburn, E. Hyjek, S. Mathew, E. Cesarman, J. Said, and D.M. Knowles KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma Am J Surg Pathol 28 2004 1401 1416
200. H.Y. Dong, W. Wang, T.S. Uldrick, and M. Gangi Human herpesvirus 8- and Epstein-Barr virus-associated solitary B cell lymphoma with a T cell immunophenotype Leuk Lymphoma 54 2013 1560 1563
201. P. Gasperini, and G. Tosato Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma Leukemia 23 2009 1867 1874
202. S. Bhatt, B.M. Ashlock, and Y. Natkunam CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma Blood 122 2013 1233 1242